4//SEC Filing
OrbiMed Israel BioFund GP Limited Partnership 4
Accession 0000947871-19-000983
CIK 0001739174other
Filed
Dec 19, 7:00 PM ET
Accepted
Dec 20, 1:58 PM ET
Size
10.2 KB
Accession
0000947871-19-000983
Insider Transaction Report
Form 4
BiomX Inc.PHGE
Transactions
- Purchase
Common Stock, $0.001 par value
2019-12-18$8.93/sh+500$4,465→ 2,309,989 total(indirect: See Footnotes) - Purchase
Common Stock, $0.001 par value
2019-12-19$8.90/sh+3,500$31,150→ 2,313,489 total(indirect: See Footnotes)
OrbiMed Israel GP Ltd.
10% Owner
Transactions
- Purchase
Common Stock, $0.001 par value
2019-12-18$8.93/sh+500$4,465→ 2,309,989 total(indirect: See Footnotes) - Purchase
Common Stock, $0.001 par value
2019-12-19$8.90/sh+3,500$31,150→ 2,313,489 total(indirect: See Footnotes)
Footnotes (3)
- [F1]The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership ("OIP LP"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,672,150 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership ("OII LP") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund"), which is the general partner of each of OIP LP and OII LP.
- [F2]By virtue of the relationships described in footnote 1, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz and Erez Chimovits. Erez Chimovits, a member of the Issuer's board of directors, is an employee of OrbiMed Israel.
- [F3]This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Documents
Issuer
BiomX Inc.
CIK 0001739174
Entity typeother
IncorporatedIsrael
Related Parties
1- filerCIK 0001569821
Filing Metadata
- Form type
- 4
- Filed
- Dec 19, 7:00 PM ET
- Accepted
- Dec 20, 1:58 PM ET
- Size
- 10.2 KB